Lansoprazole

CP-690550 was purchased from Selleck Chemicals (Houston, TX, USA). Human oncostatin M (OSM), mouse IL-6 and mouse sIL-6Ra were purchased from R&D systems (Minneapolis, MN, USA). Ebastine, cetirizine hydorochloride, meloxicam, loxoprofen sodium hydrate, nicardipine hydrochloride, amlodipine besylate, flavoxate hydrochloride, lansoprazole, indometacin and celecoxib were purchased from Tokyo Chemical Industry (Tokyo, Japan). Sofalcone and benidipine hydrochloride were purchased from Wako Pure Chemical Industries (Osaka, Japan).

Albendazole was used commercially solution (Vermiprazole 10%, oral solution, Hipra, Spain) formulation. Lansoprazole (≥98%, analytical purity) was provided in powder form from Tokyo Chemical Industry (Product Number-L0233, Japan). Lansoprazole was dissolved in solution containing 0.9% sodium chloride and 0.05% sodium hydroxide in water as 30 mg/mL. After preparing the stock solutions of the drugs, they were diluted with 0.9% sodium chloride to the appropriate dosage amounts.
The doses of the drugs, which were chosen according to EMEA data, used in the current research were determined experimentally in the experimental research, and the standard doses were indicated in the drug package insert.

Lansoprazole was purchased from the Tokyo Chemical Industry Co. (Tokyo, Japan). p38 MAPK inhibitor SB203580 and protein biosynthesis inhibitor cycloheximide (CHX) were purchased from the FUJIFILM Wako Pure Chemical Co. (Osaka, Japan). Cisplatin was purchased from Nichi-Iko Pharmaceutical Co. (Toyama, Japan). The specific HO1 inhibitor tin-mesoporphyrin IX (SnMP) was purchased from BIOMOL Research Inc. (Plymouth Meeting, PA, USA).